Wells Fargo & Company reissued their hold rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note issued to investors on Thursday morning.

Other research analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Teva Pharmaceutical Industries from a sell rating to a strong sell rating in a research report on Wednesday, August 16th. Citigroup downgraded shares of Teva Pharmaceutical Industries from a buy rating to a neutral rating and cut their target price for the company from $32.00 to $19.00 in a research report on Wednesday, August 16th. Piper Jaffray Companies set a $16.00 target price on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Thursday. Cantor Fitzgerald set a $17.00 target price on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Monday, September 11th. Finally, Royal Bank of Canada raised their target price on shares of Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the company an underperform rating in a research report on Sunday, November 5th. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $20.65.

Teva Pharmaceutical Industries (TEVA) opened at $18.61 on Thursday. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The company has a market cap of $18,907.76, a PE ratio of 4.30 and a beta of 0.55. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $38.31.

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were paid a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date of this dividend was Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently -12.10%.

A number of hedge funds have recently added to or reduced their stakes in the stock. Fieldpoint Private Securities LLC acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $171,000. Arthur Zaske & Associates LLC acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $372,000. Sterling Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $263,000. Point72 Asset Management L.P. acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $2,200,000. Finally, Chevy Chase Trust Holdings Inc. boosted its stake in Teva Pharmaceutical Industries by 81.5% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock worth $215,000 after purchasing an additional 5,497 shares in the last quarter. Institutional investors own 52.05% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/wells-fargo-company-reaffirms-hold-rating-for-teva-pharmaceutical-industries-teva/1770791.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.